Swiss specialty chemical company Clariant has sold its Pharmaceutical Fine Chemicals unit to TowerBrook Capital Partners, L.P. for a transaction value of approximately CHF110 million ($87.6 million). The sale marks a further step in Clariant's strategy to focus its portfolio on core activities including textile and leather chemicals, and pigments and additives.

Clariant is represented on five continents with over 100 group companies, and employs approximately 23,000 people.